1 / 18

Fostair® Switch

Fostair® Switch. Karen Homan NHS Bedfordshire. Fostair® Switch. Why the switch? Supporting information Considerations / limitations How have we tackled the switch? Future work. Top 10 products (current 12 months). Seretide® use above SHA average. Alternatives to Seretide®.

opa
Download Presentation

Fostair® Switch

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Fostair® Switch Karen Homan NHS Bedfordshire

  2. Fostair® Switch • Why the switch? • Supporting information • Considerations / limitations • How have we tackled the switch? • Future work

  3. Top 10 products (current 12 months)

  4. Seretide® use above SHA average

  5. Alternatives to Seretide®

  6. Project Report Bedfordshire PCT 28 January 2011 Fostair use first line [Bedfordshire PCT] 1/10 Project: Fostair use first line Description: Fostair should be the first line choice of ICS/LABA combination for adults over the age of 18 with asthma Project Duration End: Summary

  7. QIPP • Quality • budesonide, formoterol • opportunity to review asthma management • Productivity – cheaper alternative without compromising quality and may improve quality.

  8. Supporting information • British guidelines on the management of asthma • NICE guidance TAG138 www.nice.org.uk/TA138 • Scottish Medicines Consortium • Fostair® Summary of Product Characteristics • Joint Prescribing Committee Bulletin on Fostair®

  9. British guidelines on the management of asthma “…The addition of a long-acting beta2agonist (LABA) should be considered on an individual trial basis (step 3). However, before starting a new drug or stepping up treatment, the patient’s understanding of the role of treatment, adherence to treatment, inhaler technique, and appropriate elimination of trigger factors should be confirmed. Control of asthma should be assessed after an agreed duration, depending on the desire outcome, and the LABA discontinued in the absence of benefit.”

  10. NICE guidance TAG138 • “…if treatment with an ICS and LABA is considered appropriate, the decision to use a combination device or separate devices should be made on an individual basis, taking into consideration therapeutic need and the likelihood of treatment adherence. If a combination device is chosen, then the least costly device that is suitable for the individual is recommended. For new patients, starting them on the most cost-effective option is the most straight forward way of achieving this.”

  11. Scottish Medicines Consortium • Fostair® should be used in patients for whom beclometasone and formoterol are appropriate choices of corticosteroid and LABA, respectively, and for whom a metered dose inhaler is an appropriate delivery device. It has costs similar to other combination products containing corticosteroid and LABA to which it was clinically non-inferior. The 100mcg dose of beclometasone in Fostair® is not bioequivalent to a 100mcg dose of beclometasone in several other inhaler formulations. The Fostair® summary of product characteristics contains information on transferring from these inhalers to Fostair®.

  12. Considerations / limitations • Opportunity to review asthma management • Refrigeration • 5 month shelf life once dispensed • Spacer – AeroChamber Plus • Extrafine particle size

  13. Extrafine particle size

  14. Fostair®, Seretide®, Symbicort® comparison –not an exact science! Key: BDP= Non-extra fine beclometasone dipropionate, F=Formoterol fumarate, S=Salmeterol xinafolate

  15. The Switch • Whole system and team approach • Bedfordshire and Luton Joint Prescribing Committee bulletin Fostair® • PCT Professional Executive Committee • JPC communications • Two hospital Trust DTC approval • PCT / PBC QIPP 2011 Plans

  16. JPC Recommendation • “To recommend the use of Fostair® for asthma in new patients who fulfil the licensing and NICE TAG 138 criteria. Patients on existing combination inhalers may be switched if clinically appropriate, but care must be taken as there is potential for error due to dose inequivalencies as the beclometasone in Fostair® is present as extra fine particles and so is not bio or dose equivalent to CFC-containing BDP. In addition, Fostair® has to be stored in a refrigerator prior to dispensing. Once dispensed, a 5 month shelf life is added to the label and the inhaler then does not have to be stored in a refrigerator. The JPC were mindful that this may lead to wastage should prescribers not be aware of this shelf life limitation.”

  17. Future work plans • QIPP Plans 2011 • Monitor usage using Eclipse • Work with Trusts to improve use in new patients • Switching S.O.P. • COPD

  18. Fostair® switch

More Related